Ain’t Misbehaving

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The next day, it closed at $20.15. On Oct. 21, the day’s high was $20.70; it closed at $19.59. Is this any way for Aerie’s stock to behave? The company launched…

Read More
Protocol V, LEAVO Among Retina Highlights at ARVO

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear first-time results from two highly anticipated studies on diabetic macular edema (DME) and vein occlusion. The much anticipated Protocol V results were made public at an evening symposium from the…

Read More
Will Dexycu’s Cost Inhibit Its Use?

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a single dose, instead of the usual corticosteroid eye drops he sends home with patients to treat their postoperative inflammation. But at a list price about 10 times higher than those…

Read More
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make its pitch that its cannabinoid-based therapy may succeed where others have failed – to effectively harness the benefits of marijuana in lowering intraocular pressure (IOP) without the side effects. Nemus…

Read More
Nicox Patiently Pursues Moves to Build Value

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials, with one of them recently licensed for development and commercialization in China. And while the company pulled back last fall from listing on NASDAQ, it hasn’t scrapped that plan and…

Read More
Lessons and Pearls for Moving the Dry Eye Space Forward

Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was expensive. The team decided to abandon the program, realizing that it was no longer realistic to think the device would receive a high-dollar CPT code to cover the cost of…

Read More
Explaining the Explosion in the Dry Eye Space

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest in this topic. As session moderator Preeya Gupta, MD, of Duke University Eye Center said, 10 years ago there wasn’t much of a market for dry eye or much innovation…

Read More
Can Retina Candidates Find Their Place?

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies in the space presented at the American Academy of Ophthalmology and OIS@AAO 2018. The UK-based global analytics company GlobalData projects that sales within the age-related macular degeneration (AMD) sector alone…

Read More
The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD Dr. Ahmed has been a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in innovative glaucoma surgery includes coining the term microinvasive glaucoma surgery…

Read More